がんワクチン市場：タイプ別、技術別、適応症別、エンドユーザー別、地域別、機会、予測、2018年～2032年

世界のがんワクチンの市場規模は、2025年～2032年の予測期間中に8.83%のCAGRで拡大し、2024年の87億9,000万米ドルから2032年には172億9,000万米ドルに成長すると予測されています。

ワクチンは、がんによる罹患率や死亡率を減少させるために不可欠です。市場の成長は、がん患者の増加、政府の強力な予防接種プログラム、一般市民の意識の高まりによって促進されています。WHO、GAVI、ユニセフのような政府や組織は、特に発展途上国において、大規模な予防接種キャンペーンに積極的に資金を提供し、支援しています。バイオテクノロジー大手は、大きな成果を生み出すことができるよう結集しつつあります。

さらに、mRNAや組み換えワクチンなど、ワクチン技術の進歩が開発と生産を加速させています。製薬会社やバイオテクノロジー企業による研究開発投資の増加は、HIVやがんなどの病気に対する革新的なワクチンの開発につながっています。有利な規制政策と医療費の増加が市場拡大をさらに後押ししています。高齢者人口の増加、新興国におけるヘルスケア・インフラの整備、世界のワクチン接種率の拡大は、市場の長期的な成長を維持すると予想されます。例えば、2024年3月、Merck &Co.は、さまざまなHPV株に対する幅広い防御を提供する新規の治験用多価HPVワクチンの臨床試験の開始を発表しました。さらに、男女を対象とした臨床試験において、GARDASIL9（ヒトパピローマウイルス9価、遺伝子組換え）の単回投与レジメンの安全性と有効性を、承認済みの3回投与レジメンと比較して検証する予定です。

当レポートでは、世界のがんワクチン市場について調査し、市場の概要とともに、タイプ別、技術別、適応症別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のがんワクチン市場の見通し、2018年～2032年

• 市場規模の分析と予測
• 市場シェア分析と予測
• 市場マップ分析、2024年
  • タイプ別
  • 技術別
  • 適応症別
  • エンドユーザー別
  • 地域別

第5章 北米のがんワクチン市場の見通し、2018年～2032年

第6章 欧州のがんワクチン市場の見通し、2018年～2032年

第7章 アジア太平洋のがんワクチン市場の見通し、2018年～2032年

第8章 南米のがんワクチン市場の見通し、2018年～2032年

第9章 中東・アフリカのがんワクチン市場の見通し、2018年～2032年

第10章 需要供給分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 PESTLE分析

第14章 価格分析

第15章 市場力学

第16章 市場の動向と発展

第17章 規制枠組みとイノベーション

第18章 特許の情勢

第19章 ケーススタディ

第20章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場の主要企業トップ10の情勢
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Moderna, Inc.
  • Sanofi S.A.
  • CSL Limited
  • Serum Institute of India Pvt. Ltd.
  • CureVac N.V.
  • Dendreon Pharmaceuticals LLC

第21章 戦略的提言

第22章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 2. Global Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 3. Global Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 4. Global Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 5. Global Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 6. Global Cancer Vaccines Market Share (%), By Region, 2018-2032F
• Figure 7. North America Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 8. North America Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 9. North America Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 10. North America Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 11. North America Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 12. North America Cancer Vaccines Market Share (%), By Country, 2018-2032F
• Figure 13. United States Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 14. United States Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 15. United States Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 16. United States Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 17. United States Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 18. Canada Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 19. Canada Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 20. Canada Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 21. Canada Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 22. Canada Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 23. Mexico Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 24. Mexico Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 25. Mexico Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 26. Mexico Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 27. Mexico Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 28. Europe Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 29. Europe Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 30. Europe Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 31. Europe Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 32. Europe Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 33. Europe Cancer Vaccines Market Share (%), By Country, 2018-2032F
• Figure 34. Germany Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 35. Germany Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 36. Germany Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 37. Germany Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 38. Germany Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 39. France Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 40. France Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 41. France Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 42. France Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 43. France Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 44. Italy Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 45. Italy Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 46. Italy Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 47. Italy Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 48. Italy Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 49. United Kingdom Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 50. United Kingdom Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 51. United Kingdom Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 52. United Kingdom Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 53. United Kingdom Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 54. Russia Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 55. Russia Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 56. Russia Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 57. Russia Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 58. Russia Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 59. Netherlands Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 60. Netherlands Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 61. Netherlands Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 62. Netherlands Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 63. Netherlands Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 64. Spain Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 65. Spain Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 66. Spain Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 67. Spain Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 68. Spain Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 69. Turkey Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 70. Turkey Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 71. Turkey Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 72. Turkey Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 73. Turkey Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 74. Poland Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 75. Poland Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 76. Poland Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 77. Poland Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 78. Poland Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 79. South America Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 80. South America Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 81. South America Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 82. South America Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 83. South America Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 84. South America Cancer Vaccines Market Share (%), By Country, 2018-2032F
• Figure 85. Brazil Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 86. Brazil Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 87. Brazil Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 88. Brazil Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 89. Brazil Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 90. Argentina Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 91. Argentina Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 92. Argentina Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 93. Argentina Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 94. Argentina Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 95. Asia-Pacific Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 96. Asia-Pacific Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 97. Asia-Pacific Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 98. Asia-Pacific Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 99. Asia-Pacific Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 100. Asia-Pacific Cancer Vaccines Market Share (%), By Country, 2018-2032F
• Figure 101. India Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 102. India Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 103. India Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 104. India Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 105. India Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 106. China Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 107. China Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 108. China Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 109. China Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 110. China Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 111. Japan Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 112. Japan Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 113. Japan Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 114. Japan Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 115. Japan Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 116. Australia Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 117. Australia Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 118. Australia Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 119. Australia Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 120. Australia Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 121. Vietnam Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 122. Vietnam Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 123. Vietnam Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 124. Vietnam Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 125. Vietnam Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 126. South Korea Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 127. South Korea Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 128. South Korea Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 129. South Korea Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 130. South Korea Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 131. Indonesia Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 132. Indonesia Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 133. Indonesia Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 134. Indonesia Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 135. Indonesia Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 136. Philippines Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 137. Philippines Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 138. Philippines Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 139. Philippines Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 140. Philippines Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 141. Middle East & Africa Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 142. Middle East & Africa Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 143. Middle East & Africa Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 144. Middle East & Africa Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 145. Middle East & Africa Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 146. Middle East & Africa Cancer Vaccines Market Share (%), By Country, 2018-2032F
• Figure 147. Saudi Arabia Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 148. Saudi Arabia Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 149. Saudi Arabia Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 150. Saudi Arabia Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 151. Saudi Arabia Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 152. UAE Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 153. UAE Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 154. UAE Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 155. UAE Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 156. UAE Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 157. South Africa Cancer Vaccines Market, By Value, In USD Billion, 2018-2032F
• Figure 158. South Africa Cancer Vaccines Market Share (%), By Type, 2018-2032F
• Figure 159. South Africa Cancer Vaccines Market Share (%), By Technology, 2018-2032F
• Figure 160. South Africa Cancer Vaccines Market Share (%), By Indication, 2018-2032F
• Figure 161. South Africa Cancer Vaccines Market Share (%), By End-user, 2018-2032F
• Figure 162. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 163. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 164. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 165. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024

Global cancer vaccines market is projected to witness a CAGR of 8.83% during the forecast period 2025-2032, growing from USD 8.79 billion in 2024 to USD 17.29 billion in 2032.

Vaccines are essential for reducing morbidity and mortality from cancer. The market's growth is fueled by rising cases of cancer, strong government immunization programs, and increasing public awareness. Governments and organizations like WHO, GAVI, and UNICEF are actively funding and supporting large-scale vaccination campaigns, especially in developing countries. Biotechnology giants are coming together to be able to produce big results. Additionally, advancements in vaccine technology, such as mRNA and recombinant vaccines, accelerate development and production. Increased R&D investments from pharmaceutical and biotech firms are leading to innovative vaccines for diseases such as HIV, cancer. Favourable regulatory policies and growing healthcare expenditures further support market expansion. The increasing geriatric population, rising healthcare infrastructure in emerging economies, and expanding global vaccination coverage are expected to sustain the market's long-term growth. For instance, in March 2024, Merck & Co. announced initiation of clinical trials for a novel investigational multi-valent HPV vaccine that offers broader protection against various HPV strains. In addition, the business intends to examine the safety and effectiveness of a single-dose regimen of GARDASIL9 (Human Papillomavirus 9-valent, recombinant) in comparison to the approved three-dose regimen in clinical trials involving both males and females.

Rising Prevalence of Cancer Boosts Market Demand

One of the main factors propelling the global market for cancer vaccines is the rising incidence of cancer globally. A major component in the rising cancer burden is the rising prevalence of risk factors linked to lifestyle choices, such as smoking, poor eating habits, and inactivity. There is an increased need for cancer vaccines as a result of this concerning trend, which calls for the creation of efficient therapeutic and prevention measures. For example, according to report of America Cancer Society published in 2025, new cancer cases that are expected in the United States are 2,041,910, which is an alarmingly high figure and should be addressed. The most common cancers are breast, lung, colon and rectum and prostate cancers. Around one-third of deaths from cancer are due to tobacco use, high body mass index, alcohol consumption, low fruit and vegetable intake, and lack of physical activity. In addition, air pollution is an important risk factor for lung cancer. Cancer-causing infections, such as human papillomavirus (HPV) and hepatitis, are responsible for approximately 30% of cancer cases in low- and lower-middle-income countries. Furthermore, since the chance of having cancer rises with age, the aging of the world's population is another factor contributing to the growth in cancer cases. The emphasis is now on preventive vaccines that can lower the occurrence of specific diseases, including liver cancer, cervical cancer, and others, while the need for cancer treatment options also grows. Pharmaceutical firms are therefore making significant investments in R&D to produce novel vaccines, which is fueling market expansion. The industry is being further stimulated by governments, healthcare providers, and international organizations that are aggressively promoting immunization programs and cancer awareness.

Government Support Towards Healthcare Sector Supports Market Expansion

Government programs and support are essential for the expansion of the worldwide market for cancer vaccines. Cancer-related morbidity and mortality puts an enormous burden on governments around the world, placing a greater emphasis on healthcare innovations, particularly in the treatment of cancer. Funding for cancer research, the creation of innovative treatments, and the creation of cancer vaccines are major factors propelling the market. Public-private collaborations have been formed in numerous nations to promote innovation in vaccines and immunotherapy. For instance, the United States of government provides significant funding for cancer research through organizations like the National Institutes of Health (NIH) and the National Cancer Institute (NCI). Furthermore, government initiatives that promote the approval and commercialization of novel vaccines-like expediting the licensing process and establishing vaccination reimbursement schemes-are essential. These programs not only hasten the creation of vaccinations but also lessen the financial strain on patients, increasing access to these treatments. Additionally, several countries are aggressively pushing vaccination campaigns to prevent malignancies linked to viruses, such as HPV vaccinations to prevent cervical cancer, which is increasing market demand. For instance, in January 2023, the UK government announced an investment of USD 25.13 (£20) billion for increasing R&D vaccine development. The collaboration will aim to deliver 10,000 personalized therapies to UK patients by 2030 through a new research and development hub creating jobs and strengthening the UK's position as a leader in global life sciences. The new partnership will help accelerate clinical trials of personalized immunotherapies for cancer and infectious disease vaccines.

Breast Cancer Account for a Significant Share of the Market

Breast cancer ranks among the most common cancers worldwide, placing it as a critical area of focus for research and vaccine development within the cancer vaccine sector. As the second most frequently diagnosed cancer globally and the primary cause of cancer-related fatalities among women, breast cancer has attracted significant investment aimed at discovering effective prevention and treatment strategies, including the development of cancer vaccines. The increasing incidence of breast cancer, especially in developed nations where early detection and diagnosis are more prevalent, has intensified the emphasis on vaccine research to prevent or mitigate the risk of the disease. For instance, breast cancer is the most common cancer in women. It accounts for about 30% (or 1 in 3) of all new female cancers each year. According to the American Cancer Society's estimates for breast cancer in the United States for 2025, about 316,950 new cases of invasive breast cancer will be diagnosed in women, and about 42,170 women will die from breast cancer. While vaccines such as the human papillomavirus (HPV) vaccine indirectly contribute to the reduction of certain cancers, including cervical cancer, there is a growing concentration on creating vaccines specifically targeting breast cancer. These vaccines are designed to prevent the recurrence of breast cancer by focusing on cancer-specific antigens or enhancing the immune system's ability to combat existing cancer cells.

Moreover, the prominence of breast cancer in global health dialogues has fostered heightened awareness and advocacy, leading to increased funding and policy support for vaccine research initiatives. With advancements in immunotherapy, cancer vaccines are emerging as a promising avenue for both the treatment and prevention of breast cancer. Furthermore, the rising interest in personalized medicine within oncology generates opportunities for vaccines customized to individual patient profiles, thereby expanding the market for breast cancer vaccines. Consequently, the sustained emphasis on breast cancer research is anticipated to propel the development of more targeted and effective vaccines, thereby contributing to the overall expansion of the cancer vaccines market.

North America Holds Major Market Share

North America holds the largest market share in the global market for cancer vaccines because of its strong healthcare system, cutting-edge medical research, and high patient awareness. Many pharmaceutical and biotechnology firms specializing in cancer vaccine research and development are based in the United States. Significant public and corporate investments in the area support steady advancements in vaccine development. Furthermore, North America has a well-established healthcare system and a well-established protocol for the approval of new medications, which makes advanced cancer treatments and vaccinations more widely available to the populace. Additionally, the existence of cancer vaccine reimbursement programs guarantees that patients can afford their therapies. Furthermore, the market in North America is being supported by rising healthcare costs and growing awareness of the benefits of vaccinations for cancer prevention. Leading pharmaceutical firms like Merck and GlaxoSmithKline help propel product research and commercialization, allowing the market expansion for cancer vaccines. For instance, in April 2023, Moderna, Inc., a biotechnology company that is at the forefront of messenger RNA (mRNA) therapeutics and vaccines has presented results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck & Co. Inc.'s anti-PD-1 therapy, in patients with resected high-risk melanoma (stage III/IV). Adjuvant treatment with mRNA-4157 (V940) in conjunction with KEYTRUDA improved recurrence-free survival (RFS) in the entire intention-to-treat population in a statistically significant and clinically meaningful way. It also decreased the risk of recurrence or death by 44% when compared to KEYTRUDA alone. North America maintains its position as the leading area in the worldwide market due to its comprehensive healthcare regulations and emphasis on cancer prevention.

Future Market Scenario (2025-2032F)

One of the main factors contributing to the anticipated growth of the cancer vaccines market is the increasing demand for treatment options to ensure patient safety by delivering the right quality drug or any other such chemical product. Not only that, but the rising population and cases of cancer are also factors that will always propel market growth in the future. Given that technology is advancing, we can also expect cutting-edge technology in the area. Players in this market are expanding at an unparalleled rate, introducing cost-effective and efficient technologies. For instance, OncoC4, Inc., a clinical-stage biopharmaceutical firm committed to the discovery and development of innovative biologicals for cancer therapy among patients, partnered with BioNTech SE in March 2023.

Key Players Landscape and Outlook

The key players in the market are significantly investing in the development of cancer vaccines and are utilizing strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing large-cap industry players to increase their presence and, therefore, find new opportunities in this market.

For example, the Serum Institute of India Pvt. Ltd., acquired a 20% stake in IntegriMedical, in May 2024. This acquisition is aimed at adopting a needle-free system technology.

For instance, in March 2024, BostonGene Corporation, NEC Corporation, and Transgene Biotek Ltd extended their research collaboration for the Neoantigen Cancer Vaccine TG4050 Phase I/II Clinical Trial.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Cancer Vaccines Market Outlook, 2018-2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Type
    • 4.2.1.1. Preventive Vaccines
    • 4.2.1.2. Therapeutic Vaccines
  • 4.2.2. By Technology
    • 4.2.2.1. Peptide-based vaccines
    • 4.2.2.2. Vector-based vaccines
    • 4.2.2.3. DNA/RNA-based vaccines
    • 4.2.2.4. Others
  • 4.2.3. By Indication
    • 4.2.3.1. Breast Cancer
    • 4.2.3.2. Lung Cancer
    • 4.2.3.3. Prostate Cancer
    • 4.2.3.4. Ovarian Cancer
    • 4.2.3.5. Others
  • 4.2.4. By End-user
    • 4.2.4.1. Hospitals
    • 4.2.4.2. Specialty Centers
    • 4.2.4.3. Cancer Research Institutes
    • 4.2.4.4. Others
  • 4.2.5. By Region
    • 4.2.5.1. North America
    • 4.2.5.2. Europe
    • 4.2.5.3. Asia-Pacific
    • 4.2.5.4. South America
    • 4.2.5.5. Middle East and Africa
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 4.3. Market Map Analysis, 2024
  • 4.3.1. By Type
  • 4.3.2. By Technology
  • 4.3.3. By Indication
  • 4.3.4. By End-user
  • 4.3.5. By Region

5. North America Cancer Vaccines Market Outlook, 2018-2032F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Type
    • 5.2.1.1. Preventive Vaccines
    • 5.2.1.2. Therapeutic Vaccines
  • 5.2.2. By Technology
    • 5.2.2.1. Peptide-based vaccines
    • 5.2.2.2. Vector-based vaccines
    • 5.2.2.3. DNA/RNA-based vaccines
    • 5.2.2.4. Others
  • 5.2.3. By Indication
    • 5.2.3.1. Breast Cancer
    • 5.2.3.2. Lung Cancer
    • 5.2.3.3. Prostate Cancer
    • 5.2.3.4. Ovarian Cancer
    • 5.2.3.5. Others
  • 5.2.4. By End-user
    • 5.2.4.1. Hospitals
    • 5.2.4.2. Specialty Centers
    • 5.2.4.3. Cancer Research Institutes
    • 5.2.4.4. Others
  • 5.2.5. By Country Share
    • 5.2.5.1. United States
    • 5.2.5.2. Canada
    • 5.2.5.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Cancer Vaccines Market Outlook, 2018-2032F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Type
        • 5.3.1.2.1.1. Preventive Vaccines
        • 5.3.1.2.1.2. Therapeutic Vaccines
      • 5.3.1.2.2. By Technology
        • 5.3.1.2.2.1. Peptide-based vaccines
        • 5.3.1.2.2.2. Vector-based vaccines
        • 5.3.1.2.2.3. DNA/RNA-based vaccines
        • 5.3.1.2.2.4. Others
      • 5.3.1.2.3. By Indication
        • 5.3.1.2.3.1. Breast Cancer
        • 5.3.1.2.3.2. Lung Cancer
        • 5.3.1.2.3.3. Prostate Cancer
        • 5.3.1.2.3.4. Ovarian Cancer
        • 5.3.1.2.3.5. Others
      • 5.3.1.2.4. By End-user
        • 5.3.1.2.4.1. Hospitals
        • 5.3.1.2.4.2. Specialty Centers
        • 5.3.1.2.4.3. Cancer Research Institutes
        • 5.3.1.2.4.4. Others
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Cancer Vaccines Market Outlook, 2018-2032F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Poland

7. Asia-Pacific Cancer Vaccines Market Outlook, 2018-2032F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Cancer Vaccines Market Outlook, 2018-2032F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Cancer Vaccines Market Outlook, 2018-2032F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa
• 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

• 17.1. Regulatory Approvals
• 17.2. Clinical Trials

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. Pfizer Inc.
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 20.3.2. Sun Pharmaceutical Industries Ltd.
  • 20.3.3. Merck & Co., Inc.
  • 20.3.4. GlaxoSmithKline plc
  • 20.3.5. Moderna, Inc.
  • 20.3.6. Sanofi S.A.
  • 20.3.7. CSL Limited
  • 20.3.8. Serum Institute of India Pvt. Ltd.
  • 20.3.9. CureVac N.V.
  • 20.3.10. Dendreon Pharmaceuticals LLC

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer